Given Imaging Announces Publication in Gut

Capsule Endoscopy Is A Superior Tool for Diagnosing Chronic Inflammation In Small Intestine

Feb 19, 2003 - YOQNEAM, Israel - Given Imaging Ltd. (NASDAQ: GIVN) announced today that a study published in Gut 2003;52:390-392 concluded that wireless capsule endoscopy is more effective in diagnosing patients with suspected Crohn's Disease than conventional methods, such as small bowel x-ray and endoscopy. All the patients in the study had symptoms of suspected Crohn's disease including iron deficiency anemia, abdominal pain, diarrhea and weight loss. Mean duration of symptoms before diagnosis was over 6 years. Most patients who received medication as the consequence of the diagnosis, showed good improvement of their clinical symptoms.

"The results of this study show that wireless capsule endoscopy is able to diagnose Crohn's disease more accurately than traditional methods leading to better and earlier care of patients suffering from this debilitating disorder," said Dr. Zvi Fireman, Head of the Gastroenterology Department of Hillel Yaffe Medical Center, Hadera, Israel, who conducted the study. "Now that we have made a diagnosis for these patients who have been suffering with the symptoms of Crohn's disease for over 6 years, we can start managing their treatment."

The study evaluated seventeen patients with suspected Crohn's disease whose small bowel x-rays and upper and lower gastrointestinal endoscopic findings were normal. Of the seventeen study participants, twelve were diagnosed with having Crohn's Disease of the small bowel resulting in a diagnostic yield of 71 percent. In addition, the results showed a normal appearing small bowel in the remaining five patients, ruling out the occurrence of Crohn's Disease. In conclusion, the trial demonstrated wireless capsule endoscopy as being an effective tool for diagnosing patients with suspected Crohn's Disease undetected by conventional methods.

This press release contains forward-looking statements about Given Imaging, including projections about our business, our future revenues, and our future profitability, within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. For example, statements in the future tense, words such as "anticipates," "estimates," "expects," "intends," "plans," "believes," and words and terms of similar substance used in connection with any discussion of future operating or financial performance identify such forward-looking statements. Those forward-looking statements are not guarantees of future performance and actual results could differ materially from our current expectations as a result of numerous factors, including but not limited to the following: changes in regulatory environment, our success in implementing our sales, marketing and manufacturing plan, protection and validity of patents and other intellectual property rights, the impact of currency exchange rates, the effect of competition by other companies, the outcome of future litigation, the reimbursement policies for our product from healthcare payors, quarterly variations in operating results, the possibility of armed conflict or civil or military unrest in Israel and other risks disclosed in our filings with the U.S. Securities Exchange Commission.

19.Sept.'03